ArticleBMC cancer2025

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.

Haichao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.